SAB Biotherapeutics (SABS) Receivables - Net (2020 - 2023)

SAB Biotherapeutics (SABS) has 4 years of Receivables - Net data on file, last reported at $364117.0 in Q2 2023.

• Quarterly Receivables - Net fell 96.21% year-over-year to $364117.0 in Q2 2023, while the trailing twelve-month figure through Jun 2023 was $364117.0 (down 96.21% YoY) and the FY2022 annual result came in at $5.6 million, down 30.64% from the prior year.
• Receivables - Net slipped to $364117.0 in Q2 2023, from $763123.0 in the prior quarter.
• In the past five years, Receivables - Net ranged from a high of $20.6 million in Q4 2020 to a low of $364117.0 in Q2 2023.
• A 4-year average of $8.7 million and a median of $8.8 million in 2021 frame the typical range for Receivables - Net.
• Annual changes were most pronounced in 2022 — Receivables - Net sank 30.64% — and 2023, when it tumbled 96.21%.
• Tracing SABS's Receivables - Net over 4 years: stood at $20.6 million in 2020, then tumbled by 61.06% to $8.0 million in 2021, then slumped by 30.64% to $5.6 million in 2022, then tumbled by 93.45% to $364117.0 in 2023.
• The last three Receivables - Net figures came in at $364117.0 (Q2 2023), $763123.0 (Q1 2023), and $5.6 million (Q4 2022), per Business Quant data.